| Ytd | 9.73% | |
| 1y | 37.87% |
| Open | 1153.56 | Prev Close | 1169.60 | Low | 1152.00 | High | 1179.82 | Mkt Cap | 1.05T |
| Vol | 1.39M | Avg Vol | 2.49M | EPS | 30.04 | P/E | 39.26 | Forward P/E | 24.74 |
| Beta | 0.45 | Short Ratio | 3.09 | Inst. Own | 85.32% | Dividend | 6.92 | Div Yield | 0.59 |
| Ex Div Date | 08-14 | Earning | 10-29 | 50-d Avg | 1173.48 | 200-d Avg | 1075.99 | 1yr Est | 1330.14 |
LLY News
Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow BuildsPR NewswireNEW YORK, Oct. 9,
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth explo
Lilly's largest shareholder just filed to unload nearly $350 million in stock while analysts keep ra
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targ
The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas,
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zep
Stocks slip as Gulf tanker attacks lift Brent above $105 and the 10-year yield nears 5.35%; small ca
Eli Lilly (LLY -4.39%) is trying to turn blockbuster obesity drugs into something much bigger. Its p
Eli Lilly (NYSE:LLY) held its second-quarter earnings conference call on Wednesday. Below is the com
Three sectors are higher and eight are lower in Thursday's regular session, with the top three s
Eli Lilly (LLY) reached a significant support level, and could be a good pick for investors from a t
That gap is where Whitney Tilson of Stansberry Research is doing his shopping. His case is that the
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellatio
Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raise
PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its au
Market sentiment slipped but stayed neutral as U.S. stocks fell amid rising Treasury yields; mortgag
Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Eli Lilly has attractive pipeline candidates within its core therapeutic area. The company is well-p
Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high,
Eli Lilly (LLY), the medicines and metabolic-disease company, expanded its drug-discovery partnershi
Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises
Eli Lilly's two blockbuster drug approvals that transformed the company into a pharmaceutical giant
Eli Lilly remains a compelling diversification play, especially for portfolios with significant AI e
Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.26% move from the prior day
The 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,359.12 over the
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia,
Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo N
Tompkins Financial Corp decreased its position in shares of Eli Lilly and Company (NYSE: LLY) by 2.3
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for DirectionPR NewswireNEW YORK, Oc
Ferguson Wellman Capital Management Inc. decreased its holdings in Eli Lilly and Company (NYSE: LLY)
Rockland Trust Co. cut its holdings in Eli Lilly and Company (NYSE: LLY) by 2.8% during the third qu
/PRNewswire/ -- Stock Preachers News Commentary - Wall Street closed out the week split down the mid
Eastern Bank reduced its stake in shares of Eli Lilly and Company (NYSE: LLY) by 0.9% during the und
Baker Tilly Wealth Management LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 46.0%
Park National Corp OH raised its position in Eli Lilly and Company (NYSE: LLY) by 6.5% during the th
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Eli Lilly's experimental cancer treatment, olomorasib, receives orphan drug designation from the Foo
LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales
FDA approves Eli Lilly's Jaypirca for adults with untreated CLL/SLL without 17p deletion based o
Eli Lilly's dominance in metabolic health through blockbuster weight-loss drugs. Pfizer's pivot towa
Eli Lilly and Company (NYSE:LLY) will present new data across its dermatology portfolio at the 2026
Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance
MassMutual Private Wealth and Trust FSB decreased its position in shares of Eli Lilly and Company (N
Violich Capital Management Inc. raised its position in Eli Lilly and Company (NYSE: LLY) by 151.0% d
Eli Lilly's next-gen anti-obesity medicine has posted highly encouraging clinical trial results. The
Eli Lilly dominates the weight loss drug market, one that's on track to approach $100 billion in jus